BioCentury
ARTICLE | Company News

Novartis downsizing internal efforts on CAR T in solid tumors

How Novartis is shifting gears with its CAR T development plans

December 9, 2019 2:55 AM UTC
Updated on Dec 9, 2019 at 3:03 AM UTC

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use internal talent to solve the problems of first-generation products.

“We have pivoted our strategy from internal innovation in solid tumors to external innovation and partnering,” said Jay Bradner, president of Novartis Institutes for BioMedical Research (NIBR), the R&D arm of Novartis AG (NYSE:NVS; SIX:NOVN), during the Q&A session...

BCIQ Company Profiles

NetScientific

Novartis AG